Alaska Multidisciplinary Oncology Conference

Anchorage, AK US
May 13, 2023

The Alaska Multidisciplinary Oncology Conference is a 1-day educational and scientific meeting that will focus on key clinical topics in the management of common malignancies. This conference will feature leading experts discussing the latest diagnostic, therapeutic, and supportive care strategies in cancer management. The field of oncology is continually evolving with the introduction of new targeted therapies, cellular therapies, and immunotherapy. These advances present new opportunities to tailor treatment approaches for cancer patients based on disease-related and patient-related factors. Significant disparities exist in access to continuing education for physicians practicing in rural settings. Engaging, easily accessible continuing education activities focusing on content that has practical applications for the provider may significantly impact patient outcomes. There is a need for these educational activities in rural settings to update practicing healthcare providers about recent advances in the field. This highly practical and interactive symposium will provide a unique opportunity for healthcare professionals to learn from and interact with well-known experts in the field. 

Target Audience

  • Hematologist/Oncologists
  • Oncology Physician Assistants/Nurse Practitioners
  • Oncology Pharmacists
  • Oncology Nurses

HOTEL RESERVATION

A limited number of rooms are blocked at the Hilton Anchorage for the participants of this conference at a discounted group rate of $199/night. Please book your hotel room by April 10, 2023, to receive the discounted rate. 

FOLLOW THE LINK BELOW TO BOOK YOUR HOTEL ROOM:

 https://www.hilton.com/en/book/reservation/deeplink/?ctyhocn=ANCAHHF&groupCode=AHOC&arrivaldate=2023-05-11&departuredate=2023-05-13&cid=OM,WW,HILTONLINK,EN,DirectLink&fromId=HILTONLINKDIRECT
 

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review pertinent clinical trial data for the standard of care and novel management strategies for common malignancies.
  • Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care for cancer patients.
  • Individualize management of cancer patients based on emerging data from clinical trials and evolving expert guidelines.
  • Compare and contrast the safety and efficacy profiles of novel therapeutic strategies that impact the management of common malignancies.

 

Course summary
Available credit: 
  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.
Course opens: 
11/01/2022
Course expires: 
09/01/2023
Event starts: 
05/13/2023 - 8:00am PDT
Event ends: 
05/13/2023 - 4:15pm PDT
Cost:
$300.00
Add to calendar: 

Conference Chair: Dr. Joseph Rosales

May 13, 2023

07:00 AM- 08:00 AM             Registration/ Exhibits/ Breakfast

08:00 AM – 09:30 AM          Session 1: Women’s Cancers 

Moderator: Melissa Hardesty, MD, MPH

08:00 AM – 08:30 AM           Non-Metastatic Breast Cancer - Recent Advances- Jennifer Specht, MD 

08:30 AM – 09:00 AM           Management of Metastatic Breast Cancer in 2023 - Chelsea Gawryletz, DO

09:00 AM – 09:30 AM           Advances in Management of Ovarian Cancer-  Dan Veljovich, MD

09:30 AM – 10:00 AM           Break

10:00 AM – 12:00 PM          Session 2: General Oncology

Moderator: Theodore Kim, DO

10:00 AM – 10:30 AM           Biomarker-Guided Treatment of Advanced Non-Small Cell Lung Cancer- Joseph Rosales, MD

10:30 AM – 11:00 AM           Advances in the Management of Advanced Prostate Cancer- Sandy Srinivas, MD

11:00 AM - 11:30 AM            Management of Immunotherapy Toxicities- Shailender Bhatia, MD

11:30 AM - 12:00 PM            Panel Discussion- Paul L. Weiden, MD, Aparna Basu, MD

12:00 PM – 01:00 PM            Lunch

01:00 PM – 02:30 PM           Session 3: GI Oncology 

Moderator: Joseph Rosales, MD

01:00 PM – 01:30 PM            Advances in the Management of Colorectal Cancer- Stacey Cohen M.D

01:30 PM – 02:00 PM            Updates in the Management of Gastric and GE junction Cancers - Bruce Lin, MD

02:00 PM – 02:30 PM            Panel Discussion 

02:30 PM – 03:00 PM            Break

03:00 PM – 04:00 PM           Session 4: Hematologic malignancies

Moderator: Anu Mariampillai, MD

03:00 PM – 03:30 PM            Recent Updates in Management of Diffuse Large B cell Lymphoma- Kimberly Esham, MD, MS

03:30 PM – 04:00 PM            Updates in the Management of Multiple Myeloma- Rahul Banerjee, MD, FACP

04:00 PM – 04:15 PM            Adjourn

Hilton Anchorage
500 W 3rd Ave
Anchorage, AK 99501
United States

A limited number of rooms are blocked at the Hilton Anchorage for the participants of this conference at a discounted group rate of $199/night. Please book your hotel room by April 10, 2023, to receive the discounted rate. 

Follow the link below to book your hotel room:

 https://www.hilton.com/en/book/reservation/deeplink/?ctyhocn=ANCAHHF&groupCode=AHOC&arrivaldate=2023-05-11&departuredate=2023-05-13&cid=OM,WW,HILTONLINK,EN,DirectLink&fromId=HILTONLINKDIRECT
 

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

 

Course Director(s)

Joseph Rosales, MD

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Rahul Banerjee, MD, FACP

has a financial relationship (Grant Or Contract) with Clinical Care Options;.
has a financial relationship (Independent contractor) with Guidepoint Global;.
has a financial relationship (Grant Or Contract) with Pack Health;.
has a financial relationship (Grant Or Contract) with Curio Science;.
has a financial relationship (Independent contractor) with Sanofi Pasteur;.
has a financial relationship (Independent contractor) with Janssen Oncology;.
has a financial relationship (Independent contractor) with SparkCures;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Grant Or Contract) with i3 Health;.
has a financial relationship (Independent contractor) with Clearview Healthcare Partners;.

Aparna Basu

has no relevant financial relationships to disclose at this time.

Shailender Bhatia, MD

has a financial relationship (Grant Or Contract) with Bristol Meyers Squibb;.
has a financial relationship (Grant Or Contract) with Immune Design;.
has a financial relationship (Grant Or Contract) with NantKwest;.
has a financial relationship (Grant Or Contract) with Xencor;.
has a financial relationship (Grant Or Contract) with Amphivena;.
has a financial relationship (Grant Or Contract) with Exicure;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Trisalus Life Sciences;.
has a financial relationship (Grant Or Contract) with Agenus;.
has a financial relationship (Grant Or Contract) with EMD Serono;.
has a financial relationship (Grant Or Contract) with Kuni Foundation;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with 4SC;.
has a financial relationship (Grant Or Contract) with Regeneron (fka Checkmate Pharmaceuticals);.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Nektar Therapeutics;.
has a financial relationship (Professional Services) with Regeneron/Sanofi;.

Stacey Cohen

has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Delcath;.
has a financial relationship (Independent contractor) with Proventus - Isofol;.
has a financial relationship (Independent contractor) with Kallyope;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Taiho;.

Kimberly Esham, MD, MS

has no relevant financial relationships to disclose at this time.

Chelsea Gawryletz, DO

has a financial relationship (Professional Services) with SeaGen;.
has a financial relationship (Professional Services) with Astra Zeneca ;.
has a financial relationship (Professional Services) with Daiichi Sankyo ;.
has a financial relationship (Professional Services) with Gilead;.

Bruce Lin

has a financial relationship (Independent contractor) with Exelixis;.
has a financial relationship (Independent contractor) with Seagen;.

Joseph Rosales, MD

has no relevant financial relationships to disclose at this time.

Jennifer Specht, MD

has a financial relationship (Grant Or Contract) with Minerva ;.
has a financial relationship (Grant Or Contract) with Necktar;.
has a financial relationship (Professional Services) with Sensei Biotherapeutics;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Celcuity;.
has a financial relationship (Grant Or Contract) with Abbvie ;.
has a financial relationship (Professional Services) with GSK;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Cascadian Therapeutics ;.
has a financial relationship (Professional Services) with GE Healthcare;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Myriad Pharmaceuticals;.
has a financial relationship (Other) with A2 Biotherapeutics ;.
has a financial relationship (Professional Services) with Volastra Therapeutics;.
has a financial relationship (Grant Or Contract) with Xencor;.

Sandy Srinivas, MBBS

has a financial relationship (Professional Services) with merck;.
has a financial relationship (Professional Services) with jansen;.
has a financial relationship (Professional Services) with novartis;.

Dan Veljovich, MD

has a financial relationship (Stock) with ABBV Abbvie;.
has a financial relationship (Stock) with GILD GIlead;.
has a financial relationship (Stock) with JNJ Johnson and JOhnson;.
has a financial relationship (Stock) with PFE Pfizer;.
has a financial relationship (Stock) with VEEV Veeva Systems;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Stock) with ADPT Adaptive BIotech;.
has a financial relationship (Stock) with DOCS DOximity;.
has a financial relationship (Stock) with ISRG Intuitive surgical;.
has a financial relationship (Stock) with NVTA Invitae;.
has a financial relationship (Stock) with UNH United Health;.
has a financial relationship (Independent contractor) with GSK;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Stock) with CVS CVS Health;.
has a financial relationship (Stock) with HLN Haleon PLC;.
has a financial relationship (Stock) with MRNA Moderna;.
has a financial relationship (Stock) with TDOC Teladoc;.
has a financial relationship (Independent contractor) with Eisai;.
has a financial relationship (Stock) with AZN AstraZeneca;.
has a financial relationship (Stock) with GSK;.
has a financial relationship (Stock) with MRK Merck;.
has a financial relationship (Stock) with SGEN Seattle Genetics;.

Paul Weiden, MD

has no relevant financial relationships to disclose at this time.
Moderator(s)

Melissa Hardesty, MD, MPH

has a financial relationship (Independent contractor) with Immunogen;.
has a financial relationship (Independent contractor) with GSK;.
has a financial relationship (Independent contractor) with Intuitive;.
has a financial relationship (Independent contractor) with AZ Merek;.

Theodore Kim

has no relevant financial relationships to disclose at this time.

Anusiyanthan Mariampillai, MD

has no relevant financial relationships to disclose at this time.

Joseph Rosales, MD

has no relevant financial relationships to disclose at this time.

Available Credit

  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.

 

Price

Cost:
$300.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $300

Non-physician HCP (non-industry) - $150

Industry representatives - $850

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.